VE11 logo

Aravive DB:VE11 Stock Report

Last Price

€0.039

Market Cap

€2.7m

7D

-2.5%

1Y

n/a

Updated

29 Jan, 2024

Data

Company Financials

VE11 Stock Overview

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States.

VE11 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Aravive, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aravive
Historical stock prices
Current Share PriceUS$0.039
52 Week HighUS$1.87
52 Week LowUS$0.035
Beta2.19
11 Month Change-64.86%
3 Month Change-69.29%
1 Year Changen/a
33 Year Change-99.07%
5 Year Changen/a
Change since IPO-99.97%

Recent News & Updates

Recent updates

Shareholder Returns

VE11DE BiotechsDE Market
7D-2.5%-0.3%0.8%
1Yn/a-12.1%14.0%

Return vs Industry: Insufficient data to determine how VE11 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how VE11 performed against the German Market.

Price Volatility

Is VE11's price volatile compared to industry and market?
VE11 volatility
VE11 Average Weekly Movementn/a
Biotechs Industry Average Movement6.4%
Market Average Movement4.9%
10% most volatile stocks in DE Market10.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: VE11's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine VE11's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200823n/aaravive.com

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.

Aravive, Inc. Fundamentals Summary

How do Aravive's earnings and revenue compare to its market cap?
VE11 fundamental statistics
Market cap€2.73m
Earnings (TTM)-€36.83m
Revenue (TTM)€6.46m

0.4x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VE11 income statement (TTM)
RevenueUS$6.99m
Cost of RevenueUS$53.39m
Gross Profit-US$46.39m
Other Expenses-US$6.55m
Earnings-US$39.85m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.54
Gross Margin-663.34%
Net Profit Margin-569.73%
Debt/Equity Ratio0%

How did VE11 perform over the long term?

See historical performance and comparison